Improved pasireotide response in USP8 mutant corticotroph tumours in vitro

Abstract excerpt

Cushing's disease is a rare but devastating and difficult to manage condition. The somatostatin analogue pasireotide is the only pituitary-targeting pharmaceutical approved for the treatment of Cushing's disease but is accompanied by varying efficacy and potentially severe side effects. Finding means to predict which patients are more likely to benefit from this treatment may improve their management. More than...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adrenal and Paraganglionic Tumors
• Share to Adrenal Hormones and Disorders
• Share to Pituitary Gland Disorders and Treatments